Valuation: TScan Therapeutics, Inc.

Market Cap 50.52M 43.79M 41.05M 37.43M 70.42M 4.82B 71.55M 483M 189M 2.41B 190M 186M 8.05B P/E 2026 *
-0.86x
P/E 2027 * -0.79x
Enterprise Value -48.35M -41.91M -39.29M -35.82M -67.4M -4.61B -68.48M -463M -181M -2.31B -182M -178M -7.71B EV / Sales 2026 *
-9.62x
EV / Sales 2027 * -3.72x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
12/08 TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
30/07 Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies CI
22/06 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
22/06 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
04/06 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
06/05 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02/04 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
04/03 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
27/02 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
27/02 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
19/12 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
07/12 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
15/11 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
1 day+0.39%
1 week+3.16%
Current month+5.96%
1 month-23.56%
3 months-32.13%
6 months-15.53%
Current year-21.27%
1 week 0.75
Extreme 0.751201
0.8
1 month 0.72
Extreme 0.716
1.04
Current year 0.72
Extreme 0.716
1.47
1 year 0.72
Extreme 0.716
2.57
3 years 0.72
Extreme 0.716
9.69
5 years 0.72
Extreme 0.716
14.71
10 years 0.72
Extreme 0.716
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
20/1/26 Free

General Counsel

350,000 0.6670%
20/1/26 Free

Chief Executive Officer

1,165,000 2.2203%
20/1/26 Free

Chief Technology Officer

420,000 0.8004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%+3.16%-55.52%-63.04% 50.52M
+2.07%+10.05%+77.41%+106.53% 70.1B
-0.87%+0.08%+36.96%+65.04% 54.93B
-4.04%-4.28%+3.26%+468.97% 28.89B
+0.04%+12.56%+54.67%+5.47% 23.9B
+0.28%+1.95%-17.57%-13.47% 23.3B
+0.35%+8.24%+252.94%+466.50% 18.41B
-0.59%+7.88%+40.87%-20.12% 18.77B
-0.57%+6.85%+30.20%+580.70% 16.1B
+0.70%-2.87%+31.72%+135.70% 12.48B
Average -0.22%+7.28%+45.49%+173.23% 26.69B
Weighted average by Cap. -0.06%+8.03%+55.26%+163.54%

Financials

2026 *2027 *
Net sales 5.02M 4.36M 4.08M 3.72M 7M 480M 7.12M 48.07M 18.77M 240M 18.86M 18.46M 801M 6.51M 5.64M 5.29M 4.82M 9.08M 621M 9.22M 62.3M 24.32M 311M 24.45M 23.92M 1.04B
Net income -119M -103M -96.52M -88.01M -166M -11.34B -168M -1.14B -444M -5.67B -446M -436M -18.93B -131M -113M -106M -96.79M -182M -12.47B -185M -1.25B -488M -6.24B -490M -480M -20.82B
Net Debt -98.87M -85.7M -80.34M -73.25M -138M -9.44B -140M -946M -369M -4.72B -371M -363M -15.76B -74.76M -64.8M -60.74M -55.39M -104M -7.13B -106M -715M -279M -3.57B -281M -275M -11.91B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
14/08/26 USD 0.7873 +1.85% 149,493
12/08/26 USD 0.7730 -0.49% 527,968
11/08/26 USD 0.7768 +1.28% 248,094
10/08/26 USD 0.7670 -3.67% 464,266
07/08/26 USD 0.7962 +4.32% 336,330
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7730USD
Average target price
6.000USD
Spread / Average Target
+676.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock